Acrivon Therapeutics Inc banner

Intrinsic Value

Not Available for ACRV

There is not enough data to reliably calculate the intrinsic value for Acrivon Therapeutics Inc.

Do our valuations actually work? See backtest results .

Alternatives to ACRV

Fundamental Analysis

What Acrivon Therapeutics Does

Biotechnology Health Care

Acrivon Therapeutics is a biotechnology company that develops precision cancer medicines. It is not a commercial drugmaker yet; it builds drug candidates for hard-to-treat solid tumors and tries to match those drugs to patients whose tumors are more likely to respond. Its core idea is to use tumor biology, not just the cancer’s location, to guide treatment.

Headquarters
United States of America US
Employees
39
IPO date
Nov 15, 2022
Read the full company overview
View Company Overview
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Acrivon Therapeutics insiders are buying within their usual range

Insider trading · Last trade on Oct 22, 2026

Sold $35.3k 3 insiders
Bought $114.3k 3 insiders
Trades by date
Open insider trading

Past 12 months

Continue ACRV Research

Decided on Acrivon Therapeutics? Get an email when ACRV reaches the price you’d buy at. Free with an account.

Back to Top